Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells
Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of resistance and strategies against the resistance have not been elucidated. We examined the potential of the phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002 to enhance the anti-tumor effect of cisplatin and in...
Saved in:
Published in | Journal of experimental & clinical cancer research Vol. 27; no. 1; p. 76 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
25.11.2008
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of resistance and strategies against the resistance have not been elucidated. We examined the potential of the phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002 to enhance the anti-tumor effect of cisplatin and investigated the mechanism of chemoresistance in pancreatic cancer cells using a combination therapy of cisplatin and LY294002, both in vitro and in vivo.
Cisplatin and LY294002, individually or in combination, were given to AsPC-1 and PANC-1 cell lines. Tumor growth, DNA fragments, and Akt phosphorylation were examined in vitro. To examine the therapeutic effect of cisplatin and LY294002, individually or combination an AsPC-1 tumor xenograft model was prepared for in vivo study.
Cisplatin induced growth inhibition and Akt phosphorylation in pancreatic cancer cells. LY294002 also inhibited cell proliferation but without showing Akt phosphorylation. However, the combination therapy markedly increased cleavage of caspase-3 and cytoplasmic histone-associated DNA fragments compared to the results with cisplatin alone. In the in vivo study, blocking the PI3K/Akt cascade with LY294002 increased the efficacy of cisplatin-induced inhibition of tumor growth in nude mice, suppressing half the tumor growth with cisplatin alone. There were no detectable side effects in mice treated with combination therapy.
Our studies suggest that the PI3K/Akt pathway plays an important role in cisplatin resistance of pancreatic cancer cells. The augmentation of cisplatin with PI3K/Akt inhibitor may resolve the chemoresistance problem of cisplatin, and this might be a plausible strategy for achieving tolerance for chemotherapeutic agents in pancreatic cancer therapy. |
---|---|
AbstractList | Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of resistance and strategies against the resistance have not been elucidated. We examined the potential of the phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002 to enhance the anti-tumor effect of cisplatin and investigated the mechanism of chemoresistance in pancreatic cancer cells using a combination therapy of cisplatin and LY294002, both in vitro and in vivo.
Cisplatin and LY294002, individually or in combination, were given to AsPC-1 and PANC-1 cell lines. Tumor growth, DNA fragments, and Akt phosphorylation were examined in vitro. To examine the therapeutic effect of cisplatin and LY294002, individually or combination an AsPC-1 tumor xenograft model was prepared for in vivo study.
Cisplatin induced growth inhibition and Akt phosphorylation in pancreatic cancer cells. LY294002 also inhibited cell proliferation but without showing Akt phosphorylation. However, the combination therapy markedly increased cleavage of caspase-3 and cytoplasmic histone-associated DNA fragments compared to the results with cisplatin alone. In the in vivo study, blocking the PI3K/Akt cascade with LY294002 increased the efficacy of cisplatin-induced inhibition of tumor growth in nude mice, suppressing half the tumor growth with cisplatin alone. There were no detectable side effects in mice treated with combination therapy.
Our studies suggest that the PI3K/Akt pathway plays an important role in cisplatin resistance of pancreatic cancer cells. The augmentation of cisplatin with PI3K/Akt inhibitor may resolve the chemoresistance problem of cisplatin, and this might be a plausible strategy for achieving tolerance for chemotherapeutic agents in pancreatic cancer therapy. Abstract Background Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of resistance and strategies against the resistance have not been elucidated. We examined the potential of the phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002 to enhance the anti-tumor effect of cisplatin and investigated the mechanism of chemoresistance in pancreatic cancer cells using a combination therapy of cisplatin and LY294002, both in vitro and in vivo. Methods Cisplatin and LY294002, individually or in combination, were given to AsPC-1 and PANC-1 cell lines. Tumor growth, DNA fragments, and Akt phosphorylation were examined in vitro. To examine the therapeutic effect of cisplatin and LY294002, individually or combination an AsPC-1 tumor xenograft model was prepared for in vivo study. Results Cisplatin induced growth inhibition and Akt phosphorylation in pancreatic cancer cells. LY294002 also inhibited cell proliferation but without showing Akt phosphorylation. However, the combination therapy markedly increased cleavage of caspase-3 and cytoplasmic histone-associated DNA fragments compared to the results with cisplatin alone. In the in vivo study, blocking the PI3K/Akt cascade with LY294002 increased the efficacy of cisplatin-induced inhibition of tumor growth in nude mice, suppressing half the tumor growth with cisplatin alone. There were no detectable side effects in mice treated with combination therapy. Conclusion Our studies suggest that the PI3K/Akt pathway plays an important role in cisplatin resistance of pancreatic cancer cells. The augmentation of cisplatin with PI3K/Akt inhibitor may resolve the chemoresistance problem of cisplatin, and this might be a plausible strategy for achieving tolerance for chemotherapeutic agents in pancreatic cancer therapy. BACKGROUND: Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of resistance and strategies against the resistance have not been elucidated. We examined the potential of the phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002 to enhance the anti-tumor effect of cisplatin and investigated the mechanism of chemoresistance in pancreatic cancer cells using a combination therapy of cisplatin and LY294002, both in vitro and in vivo. METHODS: Cisplatin and LY294002, individually or in combination, were given to AsPC-1 and PANC-1 cell lines. Tumor growth, DNA fragments, and Akt phosphorylation were examined in vitro. To examine the therapeutic effect of cisplatin and LY294002, individually or combination an AsPC-1 tumor xenograft model was prepared for in vivo study. RESULTS: Cisplatin induced growth inhibition and Akt phosphorylation in pancreatic cancer cells. LY294002 also inhibited cell proliferation but without showing Akt phosphorylation. However, the combination therapy markedly increased cleavage of caspase-3 and cytoplasmic histone-associated DNA fragments compared to the results with cisplatin alone. In the in vivo study, blocking the PI3K/Akt cascade with LY294002 increased the efficacy of cisplatin-induced inhibition of tumor growth in nude mice, suppressing half the tumor growth with cisplatin alone. There were no detectable side effects in mice treated with combination therapy. CONCLUSION: Our studies suggest that the PI3K/Akt pathway plays an important role in cisplatin resistance of pancreatic cancer cells. The augmentation of cisplatin with PI3K/Akt inhibitor may resolve the chemoresistance problem of cisplatin, and this might be a plausible strategy for achieving tolerance for chemotherapeutic agents in pancreatic cancer therapy. Abstract Background Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of resistance and strategies against the resistance have not been elucidated. We examined the potential of the phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002 to enhance the anti-tumor effect of cisplatin and investigated the mechanism of chemoresistance in pancreatic cancer cells using a combination therapy of cisplatin and LY294002, both in vitro and in vivo . Methods Cisplatin and LY294002, individually or in combination, were given to AsPC-1 and PANC-1 cell lines. Tumor growth, DNA fragments, and Akt phosphorylation were examined in vitro . To examine the therapeutic effect of cisplatin and LY294002, individually or combination an AsPC-1 tumor xenograft model was prepared for in vivo study. Results Cisplatin induced growth inhibition and Akt phosphorylation in pancreatic cancer cells. LY294002 also inhibited cell proliferation but without showing Akt phosphorylation. However, the combination therapy markedly increased cleavage of caspase-3 and cytoplasmic histone-associated DNA fragments compared to the results with cisplatin alone. In the in vivo study, blocking the PI3K/Akt cascade with LY294002 increased the efficacy of cisplatin-induced inhibition of tumor growth in nude mice, suppressing half the tumor growth with cisplatin alone. There were no detectable side effects in mice treated with combination therapy. Conclusion Our studies suggest that the PI3K/Akt pathway plays an important role in cisplatin resistance of pancreatic cancer cells. The augmentation of cisplatin with PI3K/Akt inhibitor may resolve the chemoresistance problem of cisplatin, and this might be a plausible strategy for achieving tolerance for chemotherapeutic agents in pancreatic cancer therapy. |
ArticleNumber | 76 |
Audience | Academic |
Author | Fujiwara, Masao Sano, Takanori Masaki, Tsutomu Hossain, Mohammad Akram Kimura, Shoji Izuishi, Kunihiko Suzuki, Yasuyuki |
AuthorAffiliation | 2 Department of Pharmacology, Faculty of Medicine, Kagawa University 1750-1, Miki, Kita, Kagawa 761-0793, Japan 1 Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University 1750-1, Miki, Kita, Kagawa 761-0793, Japan 3 Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University 1750-1, Miki, Kita, Kagawa 761-0793, Japan |
AuthorAffiliation_xml | – name: 1 Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University 1750-1, Miki, Kita, Kagawa 761-0793, Japan – name: 3 Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University 1750-1, Miki, Kita, Kagawa 761-0793, Japan – name: 2 Department of Pharmacology, Faculty of Medicine, Kagawa University 1750-1, Miki, Kita, Kagawa 761-0793, Japan |
Author_xml | – sequence: 1 givenname: Masao surname: Fujiwara fullname: Fujiwara, Masao email: mfuji@m51.sanuki.ne.jp organization: Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University 1750-1, Miki, Kita, Kagawa 761-0793, Japan. mfuji@m51.sanuki.ne.jp – sequence: 2 givenname: Kunihiko surname: Izuishi fullname: Izuishi, Kunihiko – sequence: 3 givenname: Takanori surname: Sano fullname: Sano, Takanori – sequence: 4 givenname: Mohammad Akram surname: Hossain fullname: Hossain, Mohammad Akram – sequence: 5 givenname: Shoji surname: Kimura fullname: Kimura, Shoji – sequence: 6 givenname: Tsutomu surname: Masaki fullname: Masaki, Tsutomu – sequence: 7 givenname: Yasuyuki surname: Suzuki fullname: Suzuki, Yasuyuki |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19032736$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1r3DAQxU1JaT7ac29FUOjNiSTbkn0pJKEfC1vaQ3voSYyl0VqpLS2St9D_vto4pLuQooPEmzc_Hpo5L0588FgUrxm9ZKwVV0w2ouw6IUouSymeFWePysnB-7Q4T-mOUsE61r0oTllHKy4rcVaYL8HsRpid3xC0FvVMgiXzgOTbqip_OQ8JifOD690cIln_5F1NKSfBE-3S9r4z18mwm8CTLXgdMWua6PzESDSOY3pZPLcwJnz1cF8UPz5--H77uVx__bS6vV6XvWjpXEoLKFkNmlW8wsaYumOoQUJLBVBdY4Nt1mxddRo4N0wCbxvOmLEceuTVRbFauCbAndpGN0H8owI4dS-EuFEQc7gRVdtgT01lmdWy5tiAwVZL7DpZU9EIyKz3C2u76yc0Gv0cYTyCHle8G9Qm_FZcUMlFkwE3C6B34T-A44oOk9pPTO0nprhUUmTI2wWygRzaeRuyVU8uaXWdZ8kaxmmdXZdPuPIxODmdN8a6rB81vDtoGBDGeUhh3M0u-HRsvFqMOoaUItrH_Iyq_QY-kfjN4b_98z-sXPUXQpvXTA |
CitedBy_id | crossref_primary_10_1158_1078_0432_CCR_10_0020 crossref_primary_10_1097_TA_0000000000001235 crossref_primary_10_1074_jbc_M113_469973 crossref_primary_10_3390_ijms19051462 crossref_primary_10_1038_s41598_017_01256_8 crossref_primary_10_1038_s41551_022_00949_4 crossref_primary_10_1097_TA_0000000000001593 crossref_primary_10_1007_s00277_018_3247_3 crossref_primary_10_1080_00207454_2022_2151712 crossref_primary_10_2217_fon_12_185 crossref_primary_10_1586_era_09_109 crossref_primary_10_4103_jcrt_jcrt_105_22 crossref_primary_10_1080_19336918_2015_1016686 crossref_primary_10_1016_j_canlet_2011_05_002 crossref_primary_10_1159_000327715 crossref_primary_10_3390_cancers13225796 crossref_primary_10_4155_fmc_2018_0086 crossref_primary_10_18632_oncotarget_8229 crossref_primary_10_1111_j_1349_7006_2010_01829_x crossref_primary_10_1016_j_bcp_2010_07_030 crossref_primary_10_1177_0091270010362904 crossref_primary_10_5306_wjco_v7_i5_352 crossref_primary_10_1016_j_jphs_2017_06_006 crossref_primary_10_1016_j_semcancer_2021_06_019 crossref_primary_10_1007_s12026_011_8206_1 crossref_primary_10_3892_or_2023_8643 crossref_primary_10_1097_IGC_0b013e318253499c crossref_primary_10_1042_BSR20180776 crossref_primary_10_1038_s41598_017_17652_z crossref_primary_10_1097_CAD_0000000000001024 crossref_primary_10_1016_j_biopha_2023_115813 crossref_primary_10_1186_1475_2867_13_108 crossref_primary_10_3389_fcell_2022_844028 crossref_primary_10_1590_acb371004 crossref_primary_10_3390_medicina59081474 crossref_primary_10_1097_IGC_0b013e3182021bfd crossref_primary_10_2174_1568009621666210601113144 crossref_primary_10_1002_ptr_3107 crossref_primary_10_1111_1440_1681_12693 crossref_primary_10_1371_journal_pone_0129593 crossref_primary_10_3892_ijo_2016_3804 crossref_primary_10_3892_or_2012_1856 |
Cites_doi | 10.1007/s00428-008-0676-8 10.1158/1078-0432.CCR-05-1732 10.1158/0008-5472.CAN-05-0425 10.1016/S0959-8049(03)00490-8 10.1196/annals.1397.012 10.1016/j.canlet.2007.11.022 10.1667/RR0829.1 10.1002/cncr.10591 10.1245/ASO.2006.07.011 10.1016/j.canlet.2006.10.007 10.1016/S0093-7754(03)00273-2 10.1093/annonc/mdg207 10.1038/sj.onc.1206933 10.1210/en.2005-1450 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2008 BioMed Central Ltd. Copyright © 2008 Fujiwara et al; licensee BioMed Central Ltd. 2008 Fujiwara et al; licensee BioMed Central Ltd. |
Copyright_xml | – notice: COPYRIGHT 2008 BioMed Central Ltd. – notice: Copyright © 2008 Fujiwara et al; licensee BioMed Central Ltd. 2008 Fujiwara et al; licensee BioMed Central Ltd. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM DOA |
DOI | 10.1186/1756-9966-27-76 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1756-9966 |
EndPage | 76 |
ExternalDocumentID | oai_doaj_org_article_85eb0d3f1fc742e5ade8c7e99740656a oai_biomedcentral_com_1756_9966_27_76 A191151204 10_1186_1756_9966_27_76 19032736 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GroupedDBID | --- -5E -5G -A0 -BR 0R~ 29K 2WC 4.4 5GY 5VS AAFWJ AAJSJ ACGFO ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AENEX AFGXO AFNRJ AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BFQNJ BMC C24 C6C CGR CS3 CUY CVF D-I DIK DU5 E3Z EBS ECM EIF EJD ESX F5P GROUPED_DOAJ HYE IAO IEA IHR IHW INH INR IPNFZ ITC KQ8 M48 M~E NPM O5R O5S OK1 P2P RBZ RIG RNS ROL RPM RSV SMD SOJ TR2 AAYXX ALIPV CITATION EBLON H13 PGMZT ABVAZ 5PM |
ID | FETCH-LOGICAL-b680t-7fae714ac1323e5dd491eca7a806a0c4e5e8d49f439ca22d17a285211df2abe23 |
IEDL.DBID | RPM |
ISSN | 1756-9966 0392-9078 |
IngestDate | Thu Jul 04 21:08:39 EDT 2024 Tue Sep 17 21:19:03 EDT 2024 Wed May 22 07:11:23 EDT 2024 Fri Feb 23 00:21:05 EST 2024 Fri Feb 02 04:36:49 EST 2024 Tue Aug 20 22:12:26 EDT 2024 Fri Sep 13 05:32:34 EDT 2024 Thu May 23 23:13:46 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b680t-7fae714ac1323e5dd491eca7a806a0c4e5e8d49f439ca22d17a285211df2abe23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607265/ |
PMID | 19032736 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_85eb0d3f1fc742e5ade8c7e99740656a pubmedcentral_primary_oai_pubmedcentral_nih_gov_2607265 biomedcentral_primary_oai_biomedcentral_com_1756_9966_27_76 gale_infotracmisc_A191151204 gale_infotracacademiconefile_A191151204 gale_healthsolutions_A191151204 crossref_primary_10_1186_1756_9966_27_76 pubmed_primary_19032736 |
PublicationCentury | 2000 |
PublicationDate | 2008-11-25 |
PublicationDateYYYYMMDD | 2008-11-25 |
PublicationDate_xml | – month: 11 year: 2008 text: 2008-11-25 day: 25 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of experimental & clinical cancer research |
PublicationTitleAlternate | J Exp Clin Cancer Res |
PublicationYear | 2008 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | 12702520 - Ann Oncol. 2003 May;14(5):675-92 11085546 - Cancer Res. 2000 Nov 1;60(21):6201-7 16767907 - J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):51-7 18171600 - Cancer Lett. 2008 Mar 8;261(1):108-19 14576837 - Oncogene. 2003 Oct 20;22(47):7265-79 15492778 - Oncol Rep. 2004 Nov;12(5):955-65 17310852 - J Exp Clin Cancer Res. 2006 Dec;25(4):601-6 16396982 - Endocrinology. 2006 Apr;147(4):1761-9 17436586 - In Vivo. 2007 Mar-Apr;21(2):339-47 12932672 - Eur J Cancer. 2003 Sep;39(13):1920-6 17125914 - Cancer Lett. 2007 Jun 18;251(1):1-16 16707604 - Clin Cancer Res. 2006 May 15;12(10):3070-7 17722999 - Radiat Res. 2007 Jul;168(1):125-33 10741711 - Clin Cancer Res. 2000 Mar;6(3):880-6 16788754 - Ann Surg Oncol. 2006 Jul;13(7):933-9 17725107 - J Exp Clin Cancer Res. 2007 Jun;26(2):261-8 11085518 - Cancer Res. 2000 Nov 1;60(21):5988-94 15149158 - J Exp Clin Cancer Res. 2004 Mar;23(1):105-12 11358816 - Cancer Res. 2001 May 15;61(10):3986-97 12115344 - Cancer. 2002 Jun 15;94(12):3127-34 17404021 - Ann N Y Acad Sci. 2007 Jan;1095:82-9 12479367 - Mol Cancer Ther. 2002 Jul;1(9):707-17 16540663 - Cancer Res. 2006 Mar 15;66(6):3126-36 17549359 - Oncol Rep. 2007 Jul;18(1):139-43 18841391 - Virchows Arch. 2008 Nov;453(5):449-55 15024710 - Histol Histopathol. 2004 Apr;19(2):495-504 12908138 - Semin Oncol. 2003 Aug;30(4 Suppl 9):71-9 AS Clark (75_CR22) 2002; 1 Y Tomita (75_CR16) 2006; 12 ZZ Chong (75_CR23) 2004; 19 M D'Incalci (75_CR15) 2003; 39 C Cinti (75_CR17) 2008; 453 T Ohta (75_CR12) 2006; 147 Z Han (75_CR20) 2007; 26 M Cantore (75_CR3) 2003; 22 G Wang (75_CR24) 2004; 12 JY Tsai (75_CR1) 2003; 30 J Hayakawa (75_CR13) 2000; 60 S Ning (75_CR14) 2007; 168 H Xing (75_CR11) 2008; 261 SS Park (75_CR19) 2007; 18 SH Kim (75_CR10) 2007; 1095 A Zalatnai (75_CR4) 2007; 21 X Yang (75_CR9) 2006; 66 K Izuishi (75_CR7) 2000; 60 J Brognard (75_CR8) 2001; 61 JP Neoptolemos (75_CR2) 2003; 14 KS Chadha (75_CR18) 2006; 13 A Brozovic (75_CR25) 2007; 251 F Kayaselcuk (75_CR26) 2004; 23 ZH Siddik (75_CR5) 2003; 22 L Hu (75_CR27) 2000; 6 Z Han (75_CR21) 2006; 25 N Itoh (75_CR6) 2002; 94 |
References_xml | – volume: 61 start-page: 3986 year: 2001 ident: 75_CR8 publication-title: Cancer Res contributor: fullname: J Brognard – volume: 453 start-page: 449 year: 2008 ident: 75_CR17 publication-title: Virchows Arch doi: 10.1007/s00428-008-0676-8 contributor: fullname: C Cinti – volume: 12 start-page: 3070 year: 2006 ident: 75_CR16 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-1732 contributor: fullname: Y Tomita – volume: 66 start-page: 3126 year: 2006 ident: 75_CR9 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-0425 contributor: fullname: X Yang – volume: 39 start-page: 1920 year: 2003 ident: 75_CR15 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(03)00490-8 contributor: fullname: M D'Incalci – volume: 22 start-page: 51 issue: 4 Suppl year: 2003 ident: 75_CR3 publication-title: J Exp Clin Cancer Res contributor: fullname: M Cantore – volume: 1095 start-page: 82 year: 2007 ident: 75_CR10 publication-title: Ann N Y Acad Sci doi: 10.1196/annals.1397.012 contributor: fullname: SH Kim – volume: 26 start-page: 261 year: 2007 ident: 75_CR20 publication-title: J Exp Clin Cancer Res contributor: fullname: Z Han – volume: 60 start-page: 6201 year: 2000 ident: 75_CR7 publication-title: Cancer Res contributor: fullname: K Izuishi – volume: 261 start-page: 108 year: 2008 ident: 75_CR11 publication-title: Cancer Lett doi: 10.1016/j.canlet.2007.11.022 contributor: fullname: H Xing – volume: 60 start-page: 5988 year: 2000 ident: 75_CR13 publication-title: Cancer Res contributor: fullname: J Hayakawa – volume: 6 start-page: 880 year: 2000 ident: 75_CR27 publication-title: Clin Cancer Res contributor: fullname: L Hu – volume: 168 start-page: 125 year: 2007 ident: 75_CR14 publication-title: Radiat Res doi: 10.1667/RR0829.1 contributor: fullname: S Ning – volume: 1 start-page: 707 year: 2002 ident: 75_CR22 publication-title: Mol Cancer Ther contributor: fullname: AS Clark – volume: 94 start-page: 3127 year: 2002 ident: 75_CR6 publication-title: Cancer doi: 10.1002/cncr.10591 contributor: fullname: N Itoh – volume: 13 start-page: 933 year: 2006 ident: 75_CR18 publication-title: Ann Surg Oncol doi: 10.1245/ASO.2006.07.011 contributor: fullname: KS Chadha – volume: 251 start-page: 1 year: 2007 ident: 75_CR25 publication-title: Cancer Lett doi: 10.1016/j.canlet.2006.10.007 contributor: fullname: A Brozovic – volume: 23 start-page: 105 year: 2004 ident: 75_CR26 publication-title: J Exp Clin Cancer Res contributor: fullname: F Kayaselcuk – volume: 12 start-page: 955 year: 2004 ident: 75_CR24 publication-title: Oncol Rep contributor: fullname: G Wang – volume: 30 start-page: 71 issue: Suppl year: 2003 ident: 75_CR1 publication-title: Seminars in Oncology doi: 10.1016/S0093-7754(03)00273-2 contributor: fullname: JY Tsai – volume: 18 start-page: 139 year: 2007 ident: 75_CR19 publication-title: Oncol Rep contributor: fullname: SS Park – volume: 14 start-page: 675 year: 2003 ident: 75_CR2 publication-title: Ann Oncol doi: 10.1093/annonc/mdg207 contributor: fullname: JP Neoptolemos – volume: 22 start-page: 7265 year: 2003 ident: 75_CR5 publication-title: Oncogene doi: 10.1038/sj.onc.1206933 contributor: fullname: ZH Siddik – volume: 147 start-page: 1761 year: 2006 ident: 75_CR12 publication-title: Endocrinology doi: 10.1210/en.2005-1450 contributor: fullname: T Ohta – volume: 21 start-page: 339 year: 2007 ident: 75_CR4 publication-title: In Vivo contributor: fullname: A Zalatnai – volume: 25 start-page: 601 year: 2006 ident: 75_CR21 publication-title: J Exp Clin Cancer Res contributor: fullname: Z Han – volume: 19 start-page: 495 year: 2004 ident: 75_CR23 publication-title: Histol Histopathol contributor: fullname: ZZ Chong |
SSID | ssj0061919 |
Score | 2.1199045 |
Snippet | Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of resistance and strategies against the resistance have not been elucidated. We... Abstract Background Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of resistance and strategies against the resistance have not... BACKGROUND: Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of resistance and strategies against the resistance have not been... Abstract Background Chemoresistance is a serious problem in pancreatic cancer, but the mechanism of resistance and strategies against the resistance have not... |
SourceID | doaj pubmedcentral biomedcentral gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 76 |
SubjectTerms | Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Cell Proliferation Chromones - therapeutic use Cisplatin Cisplatin - therapeutic use Diagnosis Dosage and administration Drug resistance Drug Synergism Drug therapy Enzyme Inhibitors - therapeutic use Humans Male Mice Mice, Inbred BALB C Mice, Nude Morpholines - therapeutic use Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - enzymology Phosphatidylinositol 3-Kinases - antagonists & inhibitors Phosphatidylinositol 3-Kinases - metabolism Phosphorylation Prognosis Proto-Oncogene Proteins c-akt - metabolism Tumor Cells, Cultured |
SummonAdditionalLinks | – databaseName: Open Access: BioMedCentral Open Access Titles dbid: RBZ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9wgEEZpKlW9VH1n2zw4VGovqIAxYPWURI2SqFvlkEhpLwgwJFYqb7TZ_v8O2HFK2ltulhk_YGaYb2z4BqEPzknrHPXE8SCJiCISLeColkpST7Wn-Zvu_Ls8PBPH5_X5HVn0vT_4TMvPEN8kSaiccEWUfIQe88RxnhLzvZ-3ky6kAbmGxyQ8svj85wb3drb_KgJS5u2fZucpJpXrJf8KQAfP0bMROeLdQdUv0FroX6In8_Hf-CvUzhdtrsXVX-BhlQZeRAz4Dp8cVeSq6yFe4a6_7Bw48RJ_-8FTtXKOFz323c11vhLaca7ah2GSGPCkxz4ZxhKnT_w3r9HZwdfT_UMy1lAgTmq6IiraoJiwHrLOKtRtKxoWvFVWU2mpF6EOGs5FwCXect4yZbmGkM7ayK0LvHqD1vtFHzYQriJAu2AFYEgHMK5xKjFJRcZVYA08Zoa-FANrrge-DJMYrMsWcCaT1GKSWgxXRskZ-nSrhunCnKBo-a_oXlJTcf98AszGjA5ndB0cbavIoofsP9S2Ddqr0ED-BKhL2hnaSUo2w3bTyc_NLlhSQkFUzNDHLJE8Hd7a23HDAoxG4swqJDcLSfBQXzS_HeznrmMNrQA3Qk9UYVlFl8qWvrvM5N-Qfyou63cPGuz36Gle98IY4fUmWl8tf4ctAFcrt53d6g9N4h93 priority: 500 providerName: BioMedCentral – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbxQhFCemB-PF-O1qVQ4meiEFhq9JT9XYVOMaDzapJwIM2Ilmttmu_38fMB1LPHjxtgFmdngfvN-bgd9D6LX3ynlPA_E8KiKSSMQI-CWVVjRQE2h5p7v-ok5OxaczeXaj1FfeE1bpgavgDoyMng5dYilAFhelG6IJOvaAgyF6qgqNmLxOpuoaDFlBKekBsVGRjOhnUh9m1MHSRrgmmWqkOej-q4lPhcZ_WayXENVun7wRj47vobszkMRHdQL30a04PUC31_On8odoWG-GUppr-oHrpg28SRjgHv76sSM_xwnCFx6n89GDT2_x5-88Fy_neDPhMF5elCuhH5cifhjWjAovAw7ZTrY4v_G_fIROjz98e39C5pIKxCtDd0QnFzUTLkAS2kU5DKJnMTjtDFWOBhFlNNCWAKYEx_nAtOMGIjwbEnc-8u4x2ps2U3yKcJcA6UUnQPgeUF3vdSaWSozryHr4mxU6bARrLyp9hs2E1m0P-JbNarFZLZZrq9UKvb1Ww3JhyVeM-nvou6ym5v6lAczIzmZk_2VGK_QqK9nW06eL29sjsKQMiqhYoTdlRHZ8eOrg5vMLII1ModWM3G9GgsOGpvtJtZ8_E-tpBzASZqIby2qm1PZM43nhAod0VHMln_0PGTxHd8puGMYIl_tob7f9HV8A5Nr5l8W7rgDU6CeQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9cgECc6E-OLcf6sbsqDib6glFLgG2OWaVym8Wt88JvMJwIUtsalnf1-TeZ_70FrJ7on3xo4aOHuuM8VuEPoqbXCWEsdscwLwgMPRHF4qoUU1FHlaPqnu_wkDlf8w1F9dJEOaJrA9aWuXcwntRpOX5x__7kHCv86KbwSL8ECChJxO2GSSHEVXWO84lHcl3zeUgBHIWX5oAAICHiEaorzc0kHKZAorcCwi7-uwZ9m1isF-Z-X8tmA5Ycr_7BWB7fQzQlm4v1RLrbRFd_dRteX00b6HdQs-yYl7uqO8XikA_cBAxjEn99X5FvbgXHDbXfSWtD4AX_8ymJqc4b7Drt2fZZaQj1OKf4wrCgj-HTYRSkacNwPWN9Fq4N3X94ekinhArFC0Q2RwXhZcuPARa183TR8UXpnpFFUGOq4r72CsgAgxhnGmlIapsD-l01gxnpW3UNbXd_5BwhXAXCgNxwApwXMt7Ayhp0KJZO-XMBrCvQqm1h9NgbX0DHcdV4Dmqcjh3TkkGZSS1Gg57_ZMDdM3owS_5K-iWzK-k8F_XCsJ-3UqvaWNlUog5Oc-do0XjnpF-BsAUQTpkBPIpP1eDd1XhT0PghVhEyUF-hZooiCCl_tzHS7AWYjBtjKKHcySlBnl1XfH-XnYmCTLBZIZpKVDSmv6dqTFCkcnFXJRP3wv1s-QjfSAZmyJKzeQVub4YffBRS2sY-Tdv0CdlYuLw priority: 102 providerName: Scholars Portal |
Title | Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells |
URI | https://www.ncbi.nlm.nih.gov/pubmed/19032736 http://dx.doi.org/10.1186/1756-9966-27-76 https://pubmed.ncbi.nlm.nih.gov/PMC2607265 https://doaj.org/article/85eb0d3f1fc742e5ade8c7e99740656a |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaHhAXxJtAKT4gwcVd23FsR5zaiqogFlWISoVLZDt2G9Emq-32_3fsZBcMNy5RFNuJ7ZnxfOOMZxB6a6001lJHLPeSiCAC0QLuKqkkdVQ7mvZ051_lyZn4fF6db6FqfRYmOe072-33V9f7fXeZfCsX12629hObnc6PAIMrLqvZNtpWZbk20cflFwyClM2DguInYPnpKZ4P03IGqlKSCPAJV0Sl7EU1LUGBy7-Ou19lWioF898s2RtFlTtR_qGVjh-iBxOcxAdjtx-hLd8_Rvfm0w_zJ6idD21K0NVf4NF1Aw8BA-jDp59K8qvrQYnhrr_sLEj2En_5wWMKc46HHrvuZpFaQjlOqfwwrBwjyHTYRW5Z4rjvf_MUnR1__H50QqbECsRKTVdEBeMVE8aBKVr6qm1FzbwzymgqDXXCV17DswBgxRnOW6YM16DnWRu4sZ6Xz9BOP_T-BcJlALznjQBgaQHb1VbF8FKBceVZDZ8p0IdsYpvFGESjiWGt8xKQsCZSqIkUarhqlCzQ-zUZNg2T1aLlv1UPI5my96cHw_KimZin0ZW3tC0DC04J7ivTeu2Ur8GoAigmTYHeRCI34xnUjfA3B8BUERpRUaB3qUYUf-i1M9MpBpiNGEgrq7mb1QSxdVnx85F_fg9s4sUCqYyzsiHlJSAgKSL4JBAv_7vlK3Q_OcIwRni1i3ZWy1v_GtDWyu6lXQq4zoWG67fDn3tJ3u4AxWUqOQ |
link.rule.ids | 108,230,315,733,786,790,870,891,2115,2236,24346,24965,27957,27958,53827,53829,76169,76170 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKkYBLecNCoT4gwcW7jpPYjjiVimoLu1UPLSony3acNmqbrLbbS389YydZcDnBLfLYSZwZz3wTj2cQ-mAM18ZQSwxznGRVVhGZwVXOBaeWSkvDP935IZ-eZN9O89MNlA9nYULQvjX1uLm8Gjf1eYitXFzZyRAnNjma7wEGF4znk3voPqxXJgYnvVPA4BKEeh4UTD8B30_2GX0SySdgLDnxEJ8wQUSoX1TQFEw4v3Pg_TKyUyGd_1ppr01VHEb5h13af4x-DDPqwlEuxjcrM7a3d5I9_vOUn6CtHqni3Y78FG245hl6MO_34p-jct6WofZXc4a7qBDcVhjwJD46SMlF3YB9xHVzXhtQGks8-8l8dXSG2wbb-noRRgIdhyqBGJRSh18ttl4Ql9hvKVy_QCf7X4_3pqSv2UAMl3RFRKWdSDJtwctNXV6WWZE4q4WWlGtqM5c7CW0V4CCrGSsToZkECJGUFdPGsfQl2mzaxr1GOK0ASjqdAWY1ABsLI3zmqiphwiUFPGaEPkccU4suP4fyGbNjCixe5VmvPOsVE0rwEfo08Hc9MDhEkv_d9Yvnf3T_0NAuz1TPJCVzZ2iZVkllRcZcrksnrXAF-GuA8rgeoR0vPao73rrWK2oXpNWjLpqN0MfQw2sWeGur-wMS8DV8jq6o53bUEzSCjcivOsH8PbFeyEdIRCIbTSmmgCCGZOO94L3575E76OH0eD5Ts4PD72_RoxBvkySE5dtoc7W8ce8A1K3M-7CEfwGHlElP |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLZgSBMXxm8Kg_mABBe3jpPYjjiNQbXBOvXApMHFsh17i7alVddd9tfz7KRlHrfdqvg5rfM-v_e95vk9hD4aw7Ux1BLDHCeFLzyRBXwqueDUUmlp_E93csT3j4sfJ-XJrVZfMWnfmmbYXlwO2-Ys5lbOL-1olSc2mk72gIMLxsvRvPajh-gR7FlWrQL1zghDWBB7elBw_wTiP9lX9ckkH4HD5CTQfMIEEbGHUUVzcOP8zqH3i8RXxZL-a8O9dldpKuUt3zTeQn9Wq-pSUs6H10sztDd3Cj7ea9lP0ZOeseLdTuQZeuDa52hz0r-Tf4HqyayOPcDaU9xlh-CZx8Ar8fQgJ-dNC34SN-1ZY8B4LPDhbxa6pDM8a7FtruZxJozj2C0Qg3HqeKzFNgBygcOrhauX6Hj8_dfePul7NxDDJV0S4bUTWaEtRLu5K-u6qDJntdCSck1t4Uon4ZoHPmQ1Y3UmNJNAJbLaM20cy1-hjXbWujcI5x4opdMFcFcD9LEyIlSw8hkTLqvgawboS6I1Ne_qdKhQOTsdgU2sgvpVUL9iQgk-QJ9XOl5PjIGR5P-Lfg0YSO4fL8wWp6pXlJKlM7TOfeatKJgrde2kFa6CuA3YHtcDtBMQpLpjrmv7onYBsYF90WKAPkWJYGHgV1vdH5SApxFqdSWS24kkWAabDL_uwPlvYT3QB0gksE2WlI4AGGPR8R58b-89cwdtTr-N1eHB0c936HFMu8kywspttLFcXLv3wO2W5kPcxX8Bz2JLzw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Modulating+effect+of+the+PI3-kinase+inhibitor+LY294002+on+cisplatin+in+human+pancreatic+cancer+cells&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Fujiwara%2C+Masao&rft.au=Izuishi%2C+Kunihiko&rft.au=Sano%2C+Takanori&rft.au=Hossain%2C+Mohammad+Akram&rft.date=2008-11-25&rft.pub=BioMed+Central&rft.issn=0392-9078&rft.eissn=1756-9966&rft.volume=27&rft.issue=1&rft.spage=76&rft.epage=76&rft_id=info:doi/10.1186%2F1756-9966-27-76&rft_id=info%3Apmid%2F19032736&rft.externalDBID=PMC2607265 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |